NSCLC

This study tested two experimental drugs, AK119 and AK112, with or without chemotherapy, in people with a specific type of advanced lung cancer (EGFR-mutant non-squamous non-small cell lung cancer) that had stopped responding to standard targeted therapy. The goal was to see if t…

This early-stage study tested a new drug, BG-60366, designed to break down a faulty protein (mutant EGFR) that drives growth in some lung cancers. The trial aimed to find a safe dose and see if the drug could shrink tumors in people with advanced non-small cell lung cancer that h…

This study tested an experimental drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the study…

This study tested whether adding ociperlimab to tislelizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that hasn't been treated before. Participants had high levels of a protein called PD-L1 on their tumors. The trial was terminated…

This early-stage trial tested an experimental drug called MYTX-011 in people with advanced non-small cell lung cancer (NSCLC) that had spread or come back after standard treatments. The drug is an antibody-drug conjugate designed to deliver a powerful chemotherapy directly to can…

This study looked at 21 people with advanced lung cancer to see if a blood test (liquid biopsy) could find EGFR gene mutations as accurately as a standard tumor biopsy. Researchers compared results from three different lab methods. The goal was to improve how doctors detect these…

This pilot study aimed to see how consistently PET-MRI scans could map differences within lung tumors in people with advanced non-small cell lung cancer. Only 11 participants were enrolled before the study was stopped. The goal was to improve understanding of tumor heterogeneity,…

This study monitored drug levels in the blood of 80 patients with advanced non-small cell lung cancer who were receiving pembrolizumab (immunotherapy) alone or with chemotherapy. Researchers wanted to see if drug levels were linked to how well the cancer responded or if side effe…